Seeking Alpha

GlaxoSmithKline (GSK) reaches a $150M preliminary settlement with U.S. drug wholesalers claiming...

GlaxoSmithKline (GSK) reaches a $150M preliminary settlement with U.S. drug wholesalers claiming the company improperly delayed the market entry of competitive generic alternatives to its nasal spray Flonase. The settlement was reached with AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK), among others, who maintained that GSK had abused the citizen's petition process to monopolize the market and overcharge for the spray by restricting access to less expensive generic versions.
Comments (1)
  • TwistTie
    , contributor
    Comments (2477) | Send Message
     
    Bears: 2, Bulls: 0

     

    And I just started following this one.
    19 Dec 2012, 04:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|